Detection of Barrett s Esophagus in Patients Without Gastroesophageal Reflux Disease (GERD) Symptoms
Overview
- Phase
- Not Applicable
- Intervention
- EsoCheck/EsoGuard (EC/EG)
- Conditions
- Barrett's Esophagus
- Sponsor
- Case Comprehensive Cancer Center
- Enrollment
- 132
- Locations
- 1
- Primary Endpoint
- Positive Predictive Value (PPV) of EC/EG in a Non-GERD Population That Has Three or More Non-GERD Risk Factors for BE.
- Status
- Completed
- Last Updated
- last month
Overview
Brief Summary
The purpose of this study is to develop a method to detect Barrett's esophagus (BE) in individuals with a new office-based diagnostic test.
Detailed Description
This study will investigate whether using EsoCheck/EsoGuard(EC/EG) can detect BE in individuals at risk for BE who are currently not being detected and are not undergoing routine esophago-gastro-duodenoscopy (EGD) BE can only be diagnosed by performing upper endoscopy. Up to 500 adults who have risk factors for BE but do not have chronic heartburn or regurgitation will be enrolled in this study. This will include the EsoCheck/EsoGuard determination along with the upper endoscopy for qualifying EsoGuard negative subjects
Investigators
Eligibility Criteria
Inclusion Criteria
- •No known coagulopathy, no known esophageal varices.
- •No significant dysphagia or odynophagia
- •Absence of chronic GERD, defined as five or more years of heartburn or regurgitation with symptoms at least once a week when not on medications for GERD symptoms.
- •Subjects to qualify must meet criterion 3, be over age 50, and have two additional risk factors for BE (white race, central obesity defined as waist size \>35 inches for women and \>40 inches for men, male gender, current smoker or smoking history \>10 pack years, confirmed family history in at least two members with one being a first degree relative).
Exclusion Criteria
- •History of prior EGD procedure
- •Inability to provide written informed consent
- •History of weekly of more frequent heartburn or regurgitation for five or more years
- •On anti-coagulant drug(s)that cannot be temporarily discontinued or coagulopathy with international normalized ratio (INR) \> 1.5
- •Known history of esophageal varices or esophageal stricture
- •Any contraindication, as deemed inInvestigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGDprocedure,and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and/or esophageal ulceration
- •History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
- •Oropharyngeal tumor
- •History of esophageal or gastric surgery, with exception on uncomplicated surgical fundoplication procedure
- •History of myocardial infarction or cerebrovascular accident within past 6 months
Arms & Interventions
EC/EG & EGD
Participants will complete a study questionnaire about reflux symptoms. Performance of an EsoCheck (EC) procedure; the EC sample will subsequently be tested with the EsoGuard (EG) assay If EG assay results come back positive, participant is requested to complete standard of care (SOC) upper endoscopy (tissue samples collected) If EG assay results come back negative, selected participants (100 volunteers) will also undergo a research EGD if they consent
Intervention: EsoCheck/EsoGuard (EC/EG)
EC/EG & EGD
Participants will complete a study questionnaire about reflux symptoms. Performance of an EsoCheck (EC) procedure; the EC sample will subsequently be tested with the EsoGuard (EG) assay If EG assay results come back positive, participant is requested to complete standard of care (SOC) upper endoscopy (tissue samples collected) If EG assay results come back negative, selected participants (100 volunteers) will also undergo a research EGD if they consent
Intervention: Esophago-gastro-duodenoscopy (EGD)
Outcomes
Primary Outcomes
Positive Predictive Value (PPV) of EC/EG in a Non-GERD Population That Has Three or More Non-GERD Risk Factors for BE.
Time Frame: Up to 2 months
PPV of EC/EG in a non-GERD population that has three or more non-GERD risk factors for BE. Participants who are at risk will be offered EC/EG. Those who are positive will undergo subsequent EGD PPV = (EC/EG positive \& EGD positive) / ((EC/EG positive \& EGD positive) + (EC/EG positive \& EGD negative))
Proportion of Participants Negative Via EC/EG Who Subsequently Are Proven Negative Via EGD
Time Frame: Up to 2 months
Negative Predictive Value (NPV): Proportion of participants negative via EC/EG who subsequently are proven negative via EGD. This will be measured by offering EGD to a proportion of patients who are EC/EG negative.